A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 2, 2009, Pages 165-169

  Amato, Robert J ^a,b   Teh, Bin S ^a,b   Henary, Haby ^a,b   Khan, Muhammad ^a,b   Saxena, Somyata ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Chemohormonal therapy; Prostate cancer; Retrospective review

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; HYPONATREMIA; INFECTION; LACRIMATION DISORDER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHENOTYPE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 61649115193     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.12.004     Document Type: Article

References (22)

1. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419
2. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
3. Pacholke H.D., Wajsman Z., Algood C.B., et al. Postoperative adjuvant and salvage radiotherapy for prostate cancer: Impact on freedom from biochemical relapse and survival. Urology 64 (2004) 982-986
4. Stephenson A.J., and Eastham J.A. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 23 (2005) 8198-8203
5. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156
6. Miller J.I., Ahmann F.R., Drach G.W., et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147 (1992) 956-961
7. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
8. Zhou P., Chen M.H., McLeod D., et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992-6998
9. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
10. Bagley C., Lane R., Blasko J., et al. Adjuvant chemotherapy and hormonal therapy of high risk prostate cancer. Proc Am Soc Clin Oncol 14 (1995) 230 [Abstract]
11. Osborne C.K., Blumenstein B., Crawford E.D., et al. Combined vs. sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8 (1990) 1675-1682
12. Goodin S., Medina P., Capanna T., et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 23 (2005) 3352-3357
13. Sella A., Kilbourn R., Amato R., et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12 (1994) 683
14. Amato RJ, Ellerhorst J, Bui C, et al. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol 199;1:168-72.
15. Ellerhorst J., Tu S.M., Amato R.J., et al. Phase II trial of alternating weekly chemotherapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3 (1997) 2371-2376
16. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
17. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 15
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
19. Hussain A., Dawson N., Amin P., et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 23 (2005) 2789-2796
20. Pienta K.J., Redman B., Hussain M., et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12 (1994) 2005-2012
21. Maulard-Durdux C., Dufour B., Hennequin C., et al. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 77 (1996) 1144-1148
22. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764